The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Research Report 2025
Synopsis
The global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs.
Report Scope
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Segment by Type
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs.
Report Scope
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Segment by Type
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Agonist
1.2.3 Allosteric Modulator
1.2.4 Kinase Inhibitor
1.2.5 Monoclonal Antibody
1.2.6 Others
1.3 Market by Application
1.3.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Perspective (2019-2030)
2.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Growth Trends by Region
2.2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Dynamics
2.3.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Industry Trends
2.3.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Drivers
2.3.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Challenges
2.3.4 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players by Revenue
3.1.1 Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players by Revenue (2019-2024)
3.1.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue
3.4 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Concentration Ratio
3.4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue in 2023
3.5 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Key Players Head office and Area Served
3.6 Key Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product Solution and Service
3.7 Date of Enter into Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Breakdown Data by Type
4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Type (2025-2030)
5 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Breakdown Data by Application
5.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2019-2030)
6.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024)
6.4 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2019-2030)
7.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024)
7.4 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2019-2030)
9.2 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024)
9.4 Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.1.4 Roche Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Regeneron Pharmaceuticals
11.2.1 Regeneron Pharmaceuticals Company Detail
11.2.2 Regeneron Pharmaceuticals Business Overview
11.2.3 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.2.4 Regeneron Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.2.5 Regeneron Pharmaceuticals Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.3.4 Bayer Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Santen Oy
11.4.1 Santen Oy Company Detail
11.4.2 Santen Oy Business Overview
11.4.3 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.4.4 Santen Oy Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.4.5 Santen Oy Recent Development
11.5 Kanghong Pharmaceuticals
11.5.1 Kanghong Pharmaceuticals Company Detail
11.5.2 Kanghong Pharmaceuticals Business Overview
11.5.3 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.5.4 Kanghong Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.5.5 Kanghong Pharmaceuticals Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.6.4 Novartis Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.7.4 Eli Lilly and Company Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.7.5 Eli Lilly and Company Recent Development
11.8 TRACON Pharmaceuticals
11.8.1 TRACON Pharmaceuticals Company Detail
11.8.2 TRACON Pharmaceuticals Business Overview
11.8.3 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.8.4 TRACON Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.8.5 TRACON Pharmaceuticals Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.9.4 Pfizer Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 GSK
11.10.1 GSK Company Detail
11.10.2 GSK Business Overview
11.10.3 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.10.4 GSK Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.10.5 GSK Recent Development
11.11 BIOCAD
11.11.1 BIOCAD Company Detail
11.11.2 BIOCAD Business Overview
11.11.3 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Introduction
11.11.4 BIOCAD Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
11.11.5 BIOCAD Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Agonist
Table 3. Key Players of Allosteric Modulator
Table 4. Key Players of Kinase Inhibitor
Table 5. Key Players of Monoclonal Antibody
Table 6. Key Players of Others
Table 7. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Region (2019-2024)
Table 11. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Region (2025-2030)
Table 13. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Trends
Table 14. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Drivers
Table 15. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Challenges
Table 16. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Restraints
Table 17. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Players (2019-2024)
Table 19. Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs as of 2023)
Table 20. Ranking of Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product Solution and Service
Table 24. Date of Enter into Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Type (2019-2024)
Table 28. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Type (2025-2030)
Table 30. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Application (2019-2024)
Table 32. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Application (2025-2030)
Table 34. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 49. Roche Company Detail
Table 50. Roche Business Overview
Table 51. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 52. Roche Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 53. Roche Recent Development
Table 54. Regeneron Pharmaceuticals Company Detail
Table 55. Regeneron Pharmaceuticals Business Overview
Table 56. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 57. Regeneron Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 58. Regeneron Pharmaceuticals Recent Development
Table 59. Bayer Company Detail
Table 60. Bayer Business Overview
Table 61. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 62. Bayer Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 63. Bayer Recent Development
Table 64. Santen Oy Company Detail
Table 65. Santen Oy Business Overview
Table 66. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 67. Santen Oy Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 68. Santen Oy Recent Development
Table 69. Kanghong Pharmaceuticals Company Detail
Table 70. Kanghong Pharmaceuticals Business Overview
Table 71. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 72. Kanghong Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 73. Kanghong Pharmaceuticals Recent Development
Table 74. Novartis Company Detail
Table 75. Novartis Business Overview
Table 76. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 77. Novartis Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 78. Novartis Recent Development
Table 79. Eli Lilly and Company Company Detail
Table 80. Eli Lilly and Company Business Overview
Table 81. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 82. Eli Lilly and Company Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 83. Eli Lilly and Company Recent Development
Table 84. TRACON Pharmaceuticals Company Detail
Table 85. TRACON Pharmaceuticals Business Overview
Table 86. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 87. TRACON Pharmaceuticals Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 88. TRACON Pharmaceuticals Recent Development
Table 89. Pfizer Company Detail
Table 90. Pfizer Business Overview
Table 91. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 92. Pfizer Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 93. Pfizer Recent Development
Table 94. GSK Company Detail
Table 95. GSK Business Overview
Table 96. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 97. GSK Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 98. GSK Recent Development
Table 99. BIOCAD Company Detail
Table 100. BIOCAD Business Overview
Table 101. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product
Table 102. BIOCAD Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024) & (US$ Million)
Table 103. BIOCAD Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Type: 2023 VS 2030
Figure 3. Agonist Features
Figure 4. Allosteric Modulator Features
Figure 5. Kinase Inhibitor Features
Figure 6. Monoclonal Antibody Features
Figure 7. Others Features
Figure 8. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Application: 2023 VS 2030
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Others Case Studies
Figure 13. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Report Years Considered
Figure 14. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Region: 2023 VS 2030
Figure 17. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Players in 2023
Figure 18. Global Top Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue in 2023
Figure 20. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Country (2019-2030)
Figure 22. United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Country (2019-2030)
Figure 26. Germany Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Region (2019-2030)
Figure 34. China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Country (2019-2030)
Figure 42. Mexico Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Country (2019-2030)
Figure 46. Turkey Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Roche Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 49. Regeneron Pharmaceuticals Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 50. Bayer Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 51. Santen Oy Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 52. Kanghong Pharmaceuticals Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 54. Eli Lilly and Company Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 55. TRACON Pharmaceuticals Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 56. Pfizer Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 57. GSK Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 58. BIOCAD Revenue Growth Rate in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
